Literature DB >> 2876282

A human tumour model.

A P Forrest, P A Levack, U Chetty, R A Hawkins, W R Miller, J F Smyth, T J Anderson.   

Abstract

An approach to the management of patients with large (greater than 4 cm) operable breast cancers is described. The conventional sequence of mastectomy followed by systemic therapy is reversed, allowing accurate measurements of response to individual forms of endocrine therapy or chemotherapy. Such a method not only permits individual selection of appropriate systemic therapy, but also allows clinical response to be related to histological and biochemical tumour parameters. A response was observed in eleven of twenty-three patients to endocrine treatment and in twelve of thirteen to combination chemotherapy. In five of the latter the response was histologically complete.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876282     DOI: 10.1016/s0140-6736(86)92872-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

Review 1.  Studies of apoptosis in breast cancer.

Authors:  M Parton; M Dowsett; I Smith
Journal:  BMJ       Date:  2001-06-23

2.  Primary treatment in breast cancer.

Authors:  A P Forrest; E D Anderson; U Chetty
Journal:  BMJ       Date:  1991-03-09

Review 3.  Aromatase, aromatase inhibitors, and breast cancer.

Authors:  Saranya Chumsri; Timothy Howes; Ting Bao; Gauri Sabnis; Angela Brodie
Journal:  J Steroid Biochem Mol Biol       Date:  2011-02-16       Impact factor: 4.292

4.  Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.

Authors:  D A Cameron; E D Anderson; P Levack; R A Hawkins; T J Anderson; R C Leonard; A P Forrest; U Chetty
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 5.  Primary medical therapy and breast conservation treatment: the medical oncology perspective.

Authors:  Nan Soon Wong
Journal:  Gland Surg       Date:  2018-12

6.  Conservation surgery after primary chemotherapy in large carcinomas of the breast.

Authors:  U Veronesi; G Bonadonna; S Zurrida; V Galimberti; M Greco; C Brambilla; A Luini; S Andreola; F Rilke; R Raselli
Journal:  Ann Surg       Date:  1995-11       Impact factor: 12.969

7.  Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data.

Authors:  Jeryong Kim; Jinsun Lee; Eilsung Chang; Kwangsun Suh; Cheoljoo Lee; Jongtae Jee; Hyungsub Shin
Journal:  J Breast Cancer       Date:  2011-03-31       Impact factor: 3.588

8.  Variations associated with the DNA analysis of multiple fine needle aspirates obtained from breast cancer patients.

Authors:  P Mullen; W R Miller
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

9.  Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study).

Authors:  J C Gazet; H T Ford; R C Coombes
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

10.  Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.

Authors:  E D Anderson; A P Forrest; P A Levack; U Chetty; R A Hawkins
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.